NZ217732A - Controlled release formulation for oral administration which includes either pindolol or a 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine dicarboxylate ester - Google Patents

Controlled release formulation for oral administration which includes either pindolol or a 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine dicarboxylate ester

Info

Publication number
NZ217732A
NZ217732A NZ217732A NZ21773286A NZ217732A NZ 217732 A NZ217732 A NZ 217732A NZ 217732 A NZ217732 A NZ 217732A NZ 21773286 A NZ21773286 A NZ 21773286A NZ 217732 A NZ217732 A NZ 217732A
Authority
NZ
New Zealand
Prior art keywords
benzoxadiazol
pindolol
dihydro
dimethyl
oral administration
Prior art date
Application number
NZ217732A
Other languages
English (en)
Inventor
Othmar Zuger
Original Assignee
Sandoz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858524135A external-priority patent/GB8524135D0/en
Priority claimed from GB858524653A external-priority patent/GB8524653D0/en
Priority claimed from GB858531419A external-priority patent/GB8531419D0/en
Priority claimed from GB868603097A external-priority patent/GB8603097D0/en
Priority claimed from GB868605037A external-priority patent/GB8605037D0/en
Application filed by Sandoz Ltd filed Critical Sandoz Ltd
Publication of NZ217732A publication Critical patent/NZ217732A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NZ217732A 1985-10-01 1986-09-29 Controlled release formulation for oral administration which includes either pindolol or a 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine dicarboxylate ester NZ217732A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB858524135A GB8524135D0 (en) 1985-10-01 1985-10-01 Darodipine compositions
GB858524653A GB8524653D0 (en) 1985-10-07 1985-10-07 Pharmaceutical formulations
GB858531419A GB8531419D0 (en) 1985-12-20 1985-12-20 Pindolol compositions
GB868603097A GB8603097D0 (en) 1986-02-07 1986-02-07 Pharmaceutical formulations
GB868605037A GB8605037D0 (en) 1986-02-28 1986-02-28 Oral pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NZ217732A true NZ217732A (en) 1990-07-26

Family

ID=27516617

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ217732A NZ217732A (en) 1985-10-01 1986-09-29 Controlled release formulation for oral administration which includes either pindolol or a 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine dicarboxylate ester

Country Status (20)

Country Link
KR (1) KR920008817B1 (cs)
AT (1) AT402257B (cs)
BE (1) BE905516A (cs)
CA (1) CA1298784C (cs)
CH (1) CH669524A5 (cs)
DE (1) DE3632201C2 (cs)
DK (1) DK170016B1 (cs)
ES (1) ES2002508A6 (cs)
FR (1) FR2589732B1 (cs)
GR (1) GR862457B (cs)
HK (1) HK392A (cs)
HU (1) HU197201B (cs)
IE (1) IE59589B1 (cs)
IL (1) IL80182A (cs)
LU (1) LU86615A1 (cs)
NL (1) NL194822C (cs)
NZ (1) NZ217732A (cs)
PT (1) PT83456B (cs)
SE (1) SE503222C2 (cs)
SG (1) SG103391G (cs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
WO2003065970A2 (en) * 2001-02-20 2003-08-14 Royal College Of Surgeons Ie Treatment of fibromyalgia and related fatigue syndromes using pindolol
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
DD145004A3 (de) * 1978-09-25 1980-11-19 Reinhard Huettenrauch Verfahren zur herstellung fester a zneiformen
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS6056122B2 (ja) * 1980-05-21 1985-12-09 塩野義製薬株式会社 徐放性製剤
GB2084017B (en) * 1980-09-18 1984-08-22 Sandoz Ltd Pharmaceutical compositions effective against coronary heat disease and hypertension
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions
WO1985004100A1 (en) * 1984-03-21 1985-09-26 American Home Products Corporation Sustained release pharmaceutical capsules
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤

Also Published As

Publication number Publication date
IE862565L (en) 1987-04-01
IE59589B1 (en) 1994-03-09
DK464686A (da) 1987-04-02
HK392A (en) 1992-01-10
PT83456A (en) 1986-10-01
SE503222C2 (sv) 1996-04-22
DE3632201A1 (de) 1987-04-02
NL8602370A (nl) 1987-05-04
LU86615A1 (fr) 1987-04-02
IL80182A0 (en) 1986-12-31
CH669524A5 (cs) 1989-03-31
DE3632201C2 (de) 1997-05-07
HUT44701A (en) 1988-04-28
DK170016B1 (da) 1995-05-01
SE8604112D0 (sv) 1986-09-29
AT402257B (de) 1997-03-25
NL194822B (nl) 2002-12-02
KR920008817B1 (ko) 1992-10-09
HU197201B (en) 1989-03-28
FR2589732B1 (fr) 1989-07-13
DK464686D0 (da) 1986-09-29
GR862457B (en) 1987-01-29
SG103391G (en) 1992-01-17
IL80182A (en) 1991-01-31
CA1298784C (en) 1992-04-14
ES2002508A6 (es) 1988-08-16
BE905516A (fr) 1987-03-30
KR870003777A (ko) 1987-05-04
FR2589732A1 (fr) 1987-05-15
NL194822C (nl) 2003-04-03
PT83456B (pt) 1989-05-12
SE8604112L (sv) 1987-04-02
ATA260486A (de) 1996-08-15

Similar Documents

Publication Publication Date Title
NZ219868A (en) Amlodipine salts (3 ethyl 5-methyl -2-(aminoethoxymethyl)- 4-(2-chlorophenyl)-1,4-dihydro-6-methylpyridine-3,5- dicarboxylate) and pharmaceutical compositions
DE2967573D1 (en) Use of 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridin-3-beta-methoxy ethylester-5-isopropylester for the preparation of cerebrally active drugs
AU1760988A (en) Enhancers for the transdermal flux of certain 1,4-dihydropyridine derivatives
ZA892557B (en) Pharmaceutical composition for oral administration,based on a diphosphonic acid derivative
EP0152273A3 (en) A phenylpiperidine derivative, and its salts, their preparation, compositions containing them, and their therapeutic use
IL84894A0 (en) Resolution of 1,4-dihydropyridine derivatives and optically active derivative salts of such derivatives
NZ217732A (en) Controlled release formulation for oral administration which includes either pindolol or a 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine dicarboxylate ester
DK689188D0 (da) Anvendelse af piperidin-derivater til fremstilling af et farmaceutisk praeparat
EP0406739A3 (en) Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same
FI884611L (fi) Menetelmä -/4-(1,1-dimetyylietyyli)fenyyli/-4-(hydroksidifenyylimetyyli)-1-piperidiinibutanolin farmaseuttisen koostumuksen valmistamiseksi
DE59206868D1 (de) Pharmazeutische Zubereitungen mit einer speziellen Kristallmodifikation des 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsäure-isopropyl-(2-methoxyethyl)-esters
NZ219779A (en) 3-methyl-5-(3-(4,4-diphenylpiperid-1-yl)-propyl)(+)-1,4 -dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5 dicarboxylate, its salts, preparation and medicaments
AU626404B2 (en) A controlled release formulation of 4-(2,1,3-benzoxadizaol-4 -yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine dicarboxylate ester
AU6984987A (en) Substituted 1,4-dihydropyridine ester derivatives
IL89536A0 (en) Preparation of 1,4-dihydropyridine derivatives
GB8724868D0 (en) 2-substituted 1 4-dihydropyridine derivatives
IL81998A (en) Optically active 3-methyl-5-(3-(4,4-diphenylpiperid-1-yl)-propyl)-(+)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate and its salts,processes for the preparation thereof and pharmaceutical compositions containing the same
ZA876716B (en) Pharmaceutical composition containing a 1,4-dihydropyridine derivative and an acylated 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
IT1214719B (it) Formulazioni farmaceutiche a liberazione prolungata della sostanza attiva
NZ229059A (en) Pharmaceutical compositions containing 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-ethoxycarbonyl-2,6-dimethyl-3-pyridine carboxylic acid ethyl ester
IL64244A0 (en) 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydropyridine derivatives,their production and pharmaceutical compositions containing them
PT80521A (en) Process for the preparation of esters of the 1,4-dihydro-2,6-dimethyl-3-(alcoxicarbonyl or alcoxialcoxicarbonyl)-4-(substituted phenyl) pyridin-5-carboxylic acid of stereochemical isomers and pharmaceutically acceptable salts thereof
AU1153088A (en) New aralkyl-1,4-dihydropyridines, a method for their preparation and pharmaceutical compositions containing them
AU2327788A (en) 2-alkyl and 2-alkenyl substituted 1,4-dihydropyridines, a method for their preparation and pharmaceutical compositions containing them
ZA874636B (en) 2-(aminoalkylthio)methyl-1,4-dihydropyridine,a method for the preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 890887, NOVARTIS AG, LICHTSTRASSE 35, CH-4056 BASEL, CH

Effective date: 20140409